Table 1.

Clinicopathological data of paired diagnosis and recurrence cHL cohort at the time of primary diagnosis

Total cohort (N = 60)n (%)
Sex (N = 60)  
Male 37 (62) 
Female 23 (38) 
Median age (N = 60) 26 y (4-76 y) 
Pediatric (≤18 y) 18 (30) 
Adults (>18 y) 42 (70) 
Disease stage Ann Arbor (n = 52)  
6 (12) 
II 19 (37) 
III 17 (33) 
IV 10 (19) 
Risk groups (n = 40)  
Stages I to II (n = 24)  
EORTC favorable 9 (23) 
EORTC unfavorable 15 (38) 
Stages III to IV (n = 16)  
IPS 0 to 2 8 (20) 
IPS ≥3 8 (20) 
First line treatment (n = 52)   
Chemotherapy 49 (94) 
Radiotherapy 20 (38) 
Immunotherapy 1 (2) 
Time to first recurrence (N=60)  
Median interval (range) (y) 1.5 (0.4-13.6) 
cHL subtype (N = 60)  
NSHL 34 (57) 
MCHL 22 (37) 
LRHL 1 (2) 
cHL-NOS 3 (5) 
EBV status (N = 60)  
Negative 47 (78) 
Positive 13 (22) 
Total cohort (N = 60)n (%)
Sex (N = 60)  
Male 37 (62) 
Female 23 (38) 
Median age (N = 60) 26 y (4-76 y) 
Pediatric (≤18 y) 18 (30) 
Adults (>18 y) 42 (70) 
Disease stage Ann Arbor (n = 52)  
6 (12) 
II 19 (37) 
III 17 (33) 
IV 10 (19) 
Risk groups (n = 40)  
Stages I to II (n = 24)  
EORTC favorable 9 (23) 
EORTC unfavorable 15 (38) 
Stages III to IV (n = 16)  
IPS 0 to 2 8 (20) 
IPS ≥3 8 (20) 
First line treatment (n = 52)   
Chemotherapy 49 (94) 
Radiotherapy 20 (38) 
Immunotherapy 1 (2) 
Time to first recurrence (N=60)  
Median interval (range) (y) 1.5 (0.4-13.6) 
cHL subtype (N = 60)  
NSHL 34 (57) 
MCHL 22 (37) 
LRHL 1 (2) 
cHL-NOS 3 (5) 
EBV status (N = 60)  
Negative 47 (78) 
Positive 13 (22) 

EORTC, European Organization of Research and Treatment of Cancer; IPS, international prognostic score; LRHL, lymphocyte rich Hodgkin lymphoma; NOS, not otherwise specified.

If patients received combination therapy, multiple treatment categories were applicable, making the sum of all categories >100%. For detailed information, see supplemental Table 1.